Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC) Meeting Abstract
| Authors: | Sierecki, M. R.; Rugo, H. S.; McArthur, H. L.; Traina, T. A.; Paulson, M.; Rourke, M.; Norton, L.; Seidman, A. D.; Hudis, C. A.; Dickler, M. N. |
| Abstract Title: | Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC) |
| Meeting Title: | 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 26 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2008 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2008-05-20 |
| Start Page: | 28s |
| Language: | English |
| ACCESSION: | WOS:000208457400110 |
| DOI: | 10.1200/jco.2008.26.15_suppl.589 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 589-- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
